Evaluation of Side Effects of Mitotane

N/AActive Not RecruitingNCT00568139

University of Wuerzburg400 enrolled

Overview

Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Adrenocortical Carcinoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Adrenocortical carcinoma * Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)

Locations (1)

University Hospital

Würzburg, Germany

Outcomes

Primary Outcomes

Documentation of adverse effects

Adverse effects will be documented using the NCI CTC AE v5.5

Time frame: from starting mitotane until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years) or start of additional other medical therapies

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.